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Myeloid tissue factor does not 
modulate lung inflammation or 
permeability during experimental 
acute lung injury
Ciara M. Shaver1, Brandon S. Grove1, Jennifer K. Clune1, Nigel Mackman2, Lorraine B. Ware1,3 
& Julie A. Bastarache1
Tissue factor (TF) is a critical mediator of direct acute lung injury (ALI) with global TF deficiency resulting 
in increased airspace inflammation, alveolar-capillary permeability, and alveolar hemorrhage after 
intra-tracheal lipopolysaccharide (LPS). In the lung, TF is expressed diffusely on the lung epithelium 
and intensely on cells of the myeloid lineage. We recently reported that TF on the lung epithelium, but 
not on myeloid cells, was the major source of TF during intra-tracheal LPS-induced ALI. Because of a 
growing body of literature demonstrating important pathophysiologic differences between ALI caused 
by different etiologies, we hypothesized that TF on myeloid cells may have distinct contributions to 
airspace inflammation and permeability between direct and indirect causes of ALI. To test this, we 
compared mice lacking TF on myeloid cells (TF∆mye, LysM.Cre+/−TFflox/flox) to littermate controls during 
direct (bacterial pneumonia, ventilator-induced ALI, bleomycin-induced ALI) and indirect ALI (systemic 
LPS, cecal ligation and puncture). ALI was quantified by weight loss, bronchoalveolar lavage (BAL) 
inflammatory cell number, cytokine concentration, protein concentration, and BAL procoagulant 
activity. There was no significant contribution of TF on myeloid cells in multiple models of experimental 
ALI, leading to the conclusion that TF in myeloid cells is not a major contributor to experimental ALI.
The acute respiratory distress syndrome (ARDS), a severe form of acute lung injury (ALI), causes more than 
75,000 deaths annually in the United States1 and has no specific therapies aside from use of low tidal volume ven-
tilation and conservative fluid management2,3. Most commonly, ARDS occurs in the setting of direct lung injury 
from bacterial pneumonia or in the setting of indirect lung injury from non-pulmonary sepsis4,5. The mechanisms 
underlying development of ALI and ARDS remain unclear.
Tissue factor (TF) is a trans-membrane protein critical for activation of the coagulation cascade during 
hemostasis as well as in response to tissue injury. In the lung, TF is expressed primarily on the lung epithelium 
and on cells of the myeloid lineage (monocytes, macrophages, and neutrophils)6–10. In a model of direct ALI 
caused by intra-tracheal delivery of lipopolysaccharide (LPS), global reduction of TF resulted in increased 
airspace inflammation and increased alveolar-capillary barrier permeability11, suggesting that TF is protective 
during direct ALI. In contrast, other studies using animal models of indirect ALI have suggested that TF defi-
ciency or systemic TF inhibition reduced tissue injury12–15. We recently identified that TF expressed on the lung 
epithelium was the predominant source of TF in the lung during direct LPS-induced ALI16, with no significant 
contribution of TF from myeloid cells in this model. This finding was in contrast to prior data showing that TF 
expressed on cells in the circulation was critical for the systemic response to LPS in a model of endotoxemia17. 
Because of these apparent differences in the role of TF in direct ALI compared to indirect ALI and because of 
the critical role of macrophages and neutrophils in pulmonary host defense, we sought to better understand the 
role of myeloid TF in different models of ALI. Using mice with a targeted genetic deletion of TF only in cells of 
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the myeloid lineage, we tested the hypothesis that TF on myeloid cells would be protective in models of direct 
ALI but detrimental in models of indirect ALI.
Results
Myeloid TF in direct lung injury. To test the impact of myeloid cell TF in acute lung injury, mice with mye-
loid cell TF deletion (LysM.Cre+/−TFflox/flox, referred to as TF∆mye) and littermate controls (LysM.Cre−/−TFflox/flox, 
wild-type, WT) were subjected to multiple models of ALI. Circulating blood cells from TF∆mye mice have been 
previously shown to have abrogated expression of TF mRNA during endotoxemia and peripheral blood cells from 
TF∆mye mice had a 93% reduction in pro-coagulant activity after in vitro LPS stimulation17. We independently 
confirmed deletion of myeloid TF in our colony of TF∆mye mice. Alveolar macrophages isolated from TF∆mye mice 
that were stimulated ex vivo with LPS had TF mRNA levels that were 90% lower than in cells isolated from wild-
type littermates (p = 0.019). Similarly, thioglycollate-induced peritoneal macrophages isolated from TF∆mye mice 
had TF mRNA levels 89.5% lower after LPS stimulation than cells isolated from wild-type littermates (p = 0.019). 
These studies confirm that myeloid cells in our mouse model have a functional defect in TF expression and 
activity.
We previously demonstrated that TF on myeloid cells had no significant impact on ALI due to IT LPS admin-
istration16. However, because of the critical role of myeloid cells in coordination of pulmonary innate immunity 
in response to bacterial infection, we hypothesized that TF on myeloid cells may have a prominent role during 
bacterial pneumonia. To test this possibility, mice were infected with Klebsiella pneumoniae, a common cause of 
bacterial pneumonia. WT mice developed significant weight loss (Fig. 1a) associated with increased bacterial col-
onization in the lung and spleen (Fig. 1b,c), which resolved after 72 hours. BAL inflammatory cells (Fig. 1d), KC/
CXCL-1 expression (Fig. 1e), and total BAL protein (Fig. 1f) peaked after 48 hrs in WT mice. Deletion of myeloid 
TF had no impact in this model system. WT and TF∆mye animals had indistinguishable bacterial colonization 
in the lung and similar bacterial dissemination to the spleen. Mice lacking myeloid TF had similar neutrophilic 
BAL inflammation throughout the experiment (data not shown). Expression of KC in BAL of TF∆mye mice was 
variable over time, with mice lacking myeloid TF having more BAL KC only at the 48 hr assessment, a finding 
of uncertain biological significance (Fig. 1e). In addition, isolated peritoneal macrophages from WT and TF∆mye 
Figure 1. Effect of myeloid tissue factor deletion during acute Klebsiella pneumoniae infection. There were 
no significant differences between wild-type mice (gray bars) and mice lacking myeloid tissue factor (TF∆mye) 
(black bars) in (a) weight change, (b) bacterial colonization in the lung, (c) bacterial colonization in the spleen, 
and (d) total inflammatory cell count in bronchoalveolar lavage (BAL) fluid. There was a statistical difference 
in (e) BAL KC/CXCL-1 between genotypes only at the 48hr time point (*p = 0.023). There were no significant 
differences between WT and TF∆mye mice in (f) BAL total protein. Analysis includes 4–21 mice in each genotype 
at each time point. Statistical comparisons were performed with Student’s t tests comparing genotypes at each 
time point. Data from uninfected controls (white bars) are included for reference.
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mice had similar phagocytosis and bacterial killing of K. pneumoniae in vitro (Fig. 2a). Furthermore, peritoneal 
macrophages isolated from WT and TF∆mye mice induce pro-inflammatory M1 macrophage markers, but not M2 
macrophage markers, in response to LPS in vitro (Fig. 2b). These data confirm that lack of TF had no effect on 
antimicrobial macrophage functions.
Next, we tested whether mice lacking TF on myeloid cells had altered susceptibility to mechanical lung injury 
caused by mechanical ventilation. As expected, mechanical ventilation with both low (6 mL/kg) and high (12 mL/kg) 
tidal volumes induced a significant increase in BAL protein with limited BAL inflammation in WT mice. There 
was no significant impact of myeloid TF on BAL inflammation (Fig. 3a) or BAL protein (Fig. 3b) in this model of 
direct lung injury. BAL levels of cell-free hemoglobin were below the limit of detection (10 mg/dL) in both WT 
and TF∆mye animals (data not shown).
Figure 2. Effect of deletion of myeloid TF on macrophage phagocytosis and cytokine production. 
 (a) Thioglycollate-induced peritoneal macrophages from mice lacking myeloid TF (TF∆mye) and littermate 
controls have similar attachment, phagocytosis, and killing of Klebsiella pneumoniae at multiplicity of infection 
(MOI) of 10. Similar results were obtained at MOI of 100, 500, and 1000. (b) Thioglycollate-induced peritoneal 
macrophages from TF∆mye mice and littermate controls had increased expression of M1 macrophage markers 
(CXCL10, CCL3) with no upregulation of M2 markers (Ym1, FIZZ1, Mrc1) in response to ex vivo LPS 
stimulation, with no difference between WT cells and those lacking TF (results normalized to PBS-treated 
controls).
Figure 3. Effect of myeloid tissue factor deletion during mechanical ventilation. There were no significant 
differences between wild-type (WT) mice and mice lacking myeloid tissue factor (TF∆mye) in (a) total 
inflammatory cell counts in bronchoalveolar lavage (BAL) fluid or (b) BAL total protein after 2 hours of 
mechanical ventilation at either low (6 mL/kg) or high (12 mL/kg) tidal volumes. *indicates p < 0.05 compared 
to control treated animals in each genotype. The differences between ventilated and non-ventilated control mice 
are significant showing that this model induces lung injury in WT and TF∆mye mice. Analysis includes 2–5 mice 
in each genotype. Statistical comparisons were performed by two-way ANOVA.
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We also tested whether myeloid TF had a more prominent role during prolonged inflammation using a model 
of lung injury associated with fibrosis. Mice were treated with intra-tracheal bleomycin and samples collected 
after 7 days, which coincides with the peak of lung inflammation in this model. WT and TF∆mye mice had similar 
weight changes (Fig. 4a), BAL inflammatory cell counts (Fig. 4b), BAL cell differentials (Fig. 4c,d), BAL protein 
(Fig. 4e), and BAL clot times (Fig. 4f). BAL levels of cell-free hemoglobin were below the limit of detection (10 
mg/dL) in both WT and TF∆mye animals (data not shown).
Myeloid TF during indirect acute lung injury. Indirect ALI during sepsis is predominantly an endothe-
lial injury, with secondary acute lung injury in part due to vascular leak into the alveolar space5. We hypothesized 
that myeloid TF may have a more prominent role during this injury because of activation of circulating inflam-
matory cells during sepsis. Systemic delivery of LPS over 48 hours in WT mice resulted in significant increases in 
weight loss (Fig. 5a), BAL protein (Fig. 5c), BAL KC (Fig. 5e), and plasma KC (Fig. 5f) as compared to PBS-treated 
controls, demonstrating that this model causes significant systemic inflammation, increased lung permeability, 
and elevated airspace chemokines. Contrary to our hypothesis, there were no differences between WT and TF∆mye 
mice in weight loss (Fig. 5a), BAL cell counts (Fig. 5b), BAL protein (Fig. 5c), BAL KC (Fig. 5e), or plasma KC 
Figure 4. Effect of myeloid tissue factor deletion after intra-tracheal bleomycin administration . There were 
no significant differences between wild-type (WT) mice and mice lacking myeloid tissue factor (TF∆mye) in  
(a) weight change, (b) total inflammatory cell counts in bronchoalveolar lavage (BAL) fluid, (c,d) BAL 
differential cell counts, (e) BAL total protein, or (f) BAL clot time at 7 days after bleomycin or control. *indicates 
p < 0.05 compared to control treated animals in each genotype. Analysis includes 2–3 mice in each genotype. 
Statistical comparisons were performed with Student’s t tests.
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(Fig. 5f) levels. There was no significant activation of airspace coagulation (Fig. 5d) in this model. BAL levels of 
cell-free hemoglobin were below the limit of detection (10 mg/dL) in both WT and TF∆mye animals (data not 
shown).
Finally, we tested whether myeloid TF had a significant role in the response to polymicrobial sepsis caused by 
cecal ligation and puncture (CLP), a common model of sepsis-associated end-organ injury. Although CLP does 
not cause a robust acute lung injury18, we hypothesized that loss of myeloid TF would exacerbate lung injury in 
this model. Both WT and TF∆mye mice had limited BAL inflammation (Fig. 6a), BAL protein (Fig. 6b), BAL pro-
coagulant activity (Fig. 6c), and BAL KC expression (Fig. 6d), with no differences between groups. Both groups 
of mice had increased plasma KC levels compared to sham treated mice (Fig. 6e) with no difference between 
genotypes in this measure of systemic inflammation. BAL levels of cell-free hemoglobin were below the limit of 
detection (10 mg/dL) in both WT and TF∆mye animals (data not shown).
Discussion
In this study, we demonstrate that deletion of TF on cells of the myeloid lineage has no detectable impact during 
acute lung injury caused by multiple models of direct or indirect lung injury. While these findings are consistent 
with our previous report of a limited effect of myeloid TF during intra-tracheal LPS-induced acute lung injury, the 
lack of any effect of myeloid TF is very interesting given the robust upregulation of TF in myeloid cells in models of 
lung injury. Several studies have shown a major role for TF in mediating coagulant and inflammatory responses in 
sepsis8,12–14,19–21. TF deficiency or inhibition reduced indirect acute lung injury and improved mortality in exper-
imental models of sepsis14,22,23. Baboons with experimental sepsis treated with site-activated factor VII (which 
prevents TF-induced coagulation) developed less ALI14. In a similar study, baboons given TF-pathway-inhibitor 
(TFPI) in the setting of bacteremia had reduced mortality22, suggesting a key role for TF in outcomes of sepsis. 
However, it should be pointed out that TFPI administration likely has additional effects that differ from genetic 
deletion of TF so it is difficult to make a direct comparison. In addition, after a single injection of LPS, mice with 
relative TF deficiency had less cytokine induction and increased survival23. These preclinical data were so com-
pelling that two clinical trials of systemic TF inhibition in human sepsis and in community-acquired pneumonia 
were performed, each failing to show clinical benefit with one study showing higher mortality with TF inhibition 
during pneumonia24,25. Although these studies suggest that TF is pro-inflammatory and pro-injurious, none of 
them studied cell-specific effects of TF. Our study of myeloid TF in multiple different direct and indirect ALI 
models convincingly establishes that myeloid TF does not play a significant role in ALI pathogenesis.
Figure 5. Effect of myeloid tissue factor deletion during systemic lipopolysaccharide administration. Mice 
were treated with continuous LPS infusion (8 μg/hr) via implanted osmotic pump and samples collected after 
48 hours. There were no significant differences between wild-type (gray bars) mice and mice lacking myeloid 
tissue factor (black bars) in (a) weight change, (b) total inflammatory cell count in bronchoalveolar lavage 
(BAL) fluid, (c) BAL total protein, (d) BAL clot time, (e) BAL KC/CXCL-1, or (f) plasma KC. *indicates p < 0.05 
compared to control treated animals in each genotype. Analysis includes 4–21 mice in each genotype at each 
time point. Statistical comparisons were performed by Student’s t test.
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Another distinction is that many of these studies focused on the impact of TF inhibition on systemic illness 
rather than addressing the role of TF specifically in the injured lung. TF activation is necessary for fibrin depo-
sition, which may attenuate alveolar permeability. Pawlinski et al. showed that TF on circulating hematopoietic 
cells was sufficient for activation of coagulation in plasma after exposure to systemic LPS17. In contrast, our group 
has previously shown that mice that are globally-deficient in TF (low TF mice) have increased airspace inflamma-
tion and increased lung permeability after direct LPS-mediated ALI11. This result prompted our additional inves-
tigation of the role of myeloid TF during lung injury. However, our current studies demonstrate no major effect 
of myeloid TF in multiple models of either direct or indirect lung injury, even when the injury is non-infectious. 
Furthermore, the lack of difference in systemic inflammation during polymicrobial sepsis between WT and mye-
loid TF-deficient animals is surprising and is contrary to our hypothesis that loss of myeloid TF would cause lung 
inflammation in these models that do not typically result in significant lung inflammation. Our results suggest 
that other cellular sources of TF are the primary mediators of coagulation and inflammation in response to tissue 
injury. Consistent with this concept, loss of TF on the lung epithelium exacerbates direct ALI16, whereas TF on the 
vascular endothelium may be most critical in models of sepsis as suggested by Pawlinski et al.17.
In the lung, TF is expressed on cells of the myeloid lineage, including monocytes, macrophages, and neutro-
phils6,8,11,16,26,27, albeit at total levels less than seen on the lung epithelium. Lung biopsies of patients with ARDS 
show strong staining for TF in alveolar macrophages6. In vitro, macrophages robustly upregulate TF expression 
after LPS stimulation. Similarly, neutrophils have been shown to immunostain for TF28,29. Thus, we were surprised 
that myeloid TF had no demonstrable effect during ALI. We add to the known literature of TF in macrophages by 
demonstrating that genetic deletion of TF from myeloid cells had no significant impact on macrophage phago-
cytosis or microbicidal functions (Fig. 2a) and no effect on cytokine production or macrophage polarization in 
response to LPS (Fig. 2b).
There are several potential explanations for our findings. The simplest explanation is that TF on other cell 
types contributes the majority of TF in the lungs. We recently showed that the lung epithelium contributes more 
than 70% of total lung TF both basally and in response to LPS16. Despite alveolar macrophages from TF∆mye mice 
having only 10% of WT TF mRNA levels, the overall amount of TF protein expressed in the injured lung of TF∆mye 
mice is indistinguishable from WT animals16. While macrophages often have intense TF staining on an individual 
cell, the majority of total TF in the lung is expressed on the lung epithelium. Another explanation for the lack of 
impact of myeloid TF in these models of ALI is that the importance of myeloid TF is obscured in the presence of 
TF on other cells such as the lung epithelium. In addition, while TF on the endothelium had no detected role in 
activation of coagulation in plasma after systemic LPS administration17, there are few data on the impact of TF 
on endothelial cells in other systems. Finally, because the model systems used cause relatively mild inflammatory 
lung injury, a role for myeloid TF in inflammation and coagulation during severe lung injury remains possible.
Figure 6. Effect of myeloid tissue factor deletion after cecal ligation and puncture. Wild-type (WT) 
mice and mice lacking myeloid tissue factor (TF∆mye) had similar (a) total inflammatory cell counts in 
bronchoalveolar lavage (BAL) fluid, (b) BAL total protein, (c) BAL clot time, (d) BAL KC/CXCL-1, and  
(e) plasma KC. *indicates p < 0.05 compared to control treated animals in each genotype. Analysis includes 1–2 
sham mice and 11–14 CLP mice in each genotype. Statistical comparisons were performed by Student’s t tests.
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In conclusion, despite extensive data that supports a role for TF in acute lung injury and sepsis and the sub-
stantial body of literature showing strong induction of TF expression in myeloid cells, we were unable to demon-
strate any biologically significant role for TF expressed on myeloid cells in multiple models of both direct and 
indirect acute lung injury. In the lung, further investigation of the role of TF during ALI should focus on its 
protective role on the lung epithelium and its effects on maintenance of alveolar-capillary barrier integrity during 
direct ALI.
Material and Methods
Transgenic mice. Mice with myeloid cell TF deletion (LysM.Cre+/−TFflox/flox, TF∆mye) and littermate controls 
(LysM.Cre−/−TFflox/flox, wild-type, WT) on a C57Bl/6 background were used for all experiments. Generation of 
TF∆mye animals has been previously described16,17. Male and female mice aged 7–18 weeks were used for these 
studies. All experiments were approved by the Vanderbilt Institutional Animal Care and Use Committee and 
performed in accordance with approved procedures (protocol M12–221).
Quantification of tissue factor expression. Alveolar macrophages were collected by bronchoalveolar 
lavage of untreated wild type and TF∆mye mice, adhered to tissue culture dishes for 2 hours, and washed. Peritoneal 
macrophages were collected from the abdomen in 10 mL cold PBS 3 days after intraperitoneal 3% thioglycollate 
administration. Alveolar and peritoneal macrophages were washed and then stimulated in vitro with 10 μg/mL 
LPS for 2 hours. RNA was collected with a PureLink RNA extraction kit (Ambion, Grand Island, NY) and cDNA 
generated using SuperScript VILO reagents (Invitrogen, Life Technologies, Grand Island, NY). TF mRNA 
expression was measured by quantitative real time PCR using primers for murine TF according to established 
methods11.
Measurements of acute lung injury. At each time point in each model of ALI, mice were euthanized 
and plasma was collected in citrate. Bronchoalveolar lavage (BAL) was performed with 900 μl PBS as previously 
described11,16. Lungs were removed and flash frozen. All samples were stored at − 80 °C until further study. For 
bacterial pneumonia experiments, one lung was separated and homogenized in PBS for bacterial quantification 
prior to BAL of the remaining lung with 600 μl PBS. BAL clot time, cell counts, protein, and cytokine concentra-
tions were measured as previously described11,16,30,31.
Bacterial pneumonia. Klebsiella pneumoniae serotype 2 (ATCC strain #43816, courtesy of R. Stokes 
Peebles, Vanderbilt University, Nashville, TN) was grown overnight in Luria Bertani medium, diluted in fresh 
medium, and grown for 1–2 hours prior to preparation of the inoculum. Mice were anesthetized with ketamine 
and xylazine and 2 × 103 colony forming units were administered intra-nasally32. Samples were collected after 6, 
24, 48, or 72 hours.
Ventilator-induced lung injury. Mice were anesthetized with repeated injections of pentobarbital (5 mg/g 
mouse). After undergoing tracheotomy, mice were either mechanically ventilated with either low (6 mL/kg) or 
high (12 mL/kg) tidal volumes, respiratory rate 40 breaths/min per L tidal volume, and positive end-expiratory 
pressure of 2 cm H2O or monitored without ventilation for 2 hours prior to sample collection.
Bleomycin-induced lung injury. Mice were anesthetized with isoflurane and 0.04 U bleomycin sulfate 
(Bristol-Myers Squibb Co., Princeton, NJ) in 100 μl PBS was administered IT as previously described11. Samples 
were collected after 7 days.
Systemic LPS-induced lung injury. Indirect LPS-induced lung injury was induced by continuous infu-
sion of LPS (8 μg/hr for 24 hrs) (Escherichia coli, LPS, Sigma, St. Louis, MO) or equal volume PBS delivered by 
intra-peritoneal osmotic pump (Durect, Cupertino, CA) with a single intra-peritoneal dose of LPS (3 μg/mouse) 
or PBS at the time of pump implantation16,33. Samples were collected after 48 hours.
Cecal ligation and puncture. To induce indirect lung injury by cecal ligation and puncture (CLP), mice 
were sedated with isoflurane and a midline laparotomy performed. The cecum was identified, ligated with suture, 
and punctured once with a 23-gauge needle. The peritoneum and skin were closed with sutures. Mice were fre-
quently monitored for discomfort and given narcotic pain medication preoperatively and as needed postopera-
tively. Samples were collected after 24 hours.
Macrophage phagocytosis and cytokine expression. Thioglycollate-elicited peritoneal macrophages 
were collected as described above and incubated with K. pneumoniae in vitro at a multiplicity of infection of 10. 
After 2 hours, cells were washed x 3 with PBS. Adherent bacteria were quantified by plating of cell lysates on LB 
agar. Internalized bacteria were quantified after treatment of triplicate wells with gentamicin for 1 hour prior 
to being washed x 3 with PBS. For cytokine expression, RNA was collected from peritoneal macrophages after 
3 hours of incubation with LPS. Data for LPS-treated cells collected from individual mice are normalized to 
PBS-treated macrophages from the same mouse.
Statistical Analysis. All statistical analyses were done with SPSS version 22 for Macintosh with statis-
tical consultation. P < 0.05 was considered statistically significant. Wild type and TF∆mye were compared in 
each treatment group by Student’s t tests. Non-normally distributed data were natural log transformed prior to 
analysis.
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